Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, People's Republic of China.
Eur J Hosp Pharm. 2023 Jul;30(4):e18. doi: 10.1136/ejhpharm-2021-002999. Epub 2021 Sep 8.
The purpose of this study is to report a patient who developed acute reactive thrombocytopenia while undergoing treatment with sulperazon for systemic lupus erythematosus (SLE). Sulperazon is a broad-spectrum antibiotic that can act against a wide range of microorganisms, but rarely causes severe thrombocytopenic events. We describe a 62-year-old man with new-onset acute reactive thrombocytopenia who experienced a precipitous fall in the platelet count from 168×10/L to 1×10/L within 29 hours after exposure to sulperazon. Sulperazon was immediately discontinued followed by administration of intravenous immunoglobulin for six consecutive days. The platelet count eventually recovered and petechiae at the injection sites improved. No complications secondary to acute reactive thrombocytopenia were observed except petechiae.
本研究旨在报告一例系统性红斑狼疮（SLE）患者在使用舒巴坦治疗时发生急性反应性血小板减少症的病例。舒巴坦是一种广谱抗生素，可对抗多种微生物，但很少引起严重的血小板减少症事件。我们描述了一例 62 岁男性，新诊断为急性反应性血小板减少症，在接触舒巴坦后 29 小时内血小板计数从 168×10/L 急剧下降至 1×10/L。立即停用舒巴坦，并连续 6 天给予静脉注射免疫球蛋白。血小板计数最终恢复，注射部位瘀点改善。除瘀点外，未观察到继发于急性反应性血小板减少症的任何并发症。
